Executive SummaryDiversification didn't pay off very well for Italy's Recordati Industria Chimica & Farmaceutica SPA. The company's revised growth strategy depends mostly on developing assets it already has, principally its fine chemicals business, and an already-approved calcium antagonist called lercanidipine.
You may also be interested in...
Ongoing launches, relatively stable market conditions and cost-cutting initiatives are producing record profits from Teva’s European operations, president and CEO Kåre Schultz told delegates to a J.P. Morgan Healthcare Conference.
The recruitment process for the new executive director of the European Medicines Agency seems to be running to schedule.
Compliance Corner: The 10 Best – And 10 Worst – Things You Can Do When FDA Inspects Your Firm (Part 4)
A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this fourth installment of a 10-part series, the experts address so-called back rooms used by manufacturers during an inspection.